TWIGA (2018–2022) involved KNUST in transforming weather and water observation data into actionable information services for sustainable growth in Africa.
KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI
Ghanaian technical university providing West African field research access in climate data services and infectious disease vaccine trials.
Their core work
KNUST is one of Ghana's leading technical universities, contributing field research capabilities and local scientific expertise to large international consortia. In H2020, they have worked on two distinct challenges: transforming satellite and ground-based weather and water data into practical services for farmers and water managers in Sub-Saharan Africa, and conducting Phase 1 clinical trials for a vaccine targeting invasive non-typhoidal Salmonella — a leading cause of child mortality in the region. Their core value to European-led projects is access to West African field conditions, local patient populations, and operational context that cannot be replicated from European research centers. They function as a trusted African anchor partner, providing the on-the-ground presence that makes globally relevant research actually work in African settings.
What they specialise in
Vacc-iNTS (2019–2026) places KNUST in a Phase 1 vaccine trial for invasive non-typhoidal salmonellosis, requiring clinical site capabilities and local patient cohort access.
Both TWIGA and Vacc-iNTS depend on in-country field operations — environmental monitoring and clinical observation respectively — reflecting an institutional capacity to run rigorous field studies in a West African context.
How they've shifted over time
KNUST's first H2020 engagement (2018) was in environmental science — specifically data assimilation for weather and water monitoring systems tailored to African agricultural and climate conditions. By 2019, they had joined a long-running vaccine development trial targeting invasive non-typhoidal Salmonella, representing a distinct move into clinical health research. With only two projects on record, this is less a strategic pivot and more an indication that KNUST is being recruited across sectors as a valued African field partner, with their domain-specific technical contribution shaped by the needs of each incoming consortium.
KNUST appears to be expanding from environmental data science into infectious disease and clinical research, with its long-running Vacc-iNTS commitment (ending 2026) likely to define its H2020 legacy — making it an increasingly relevant partner for health consortia requiring African clinical sites.
How they like to work
KNUST has participated exclusively as a consortium partner, never as a project coordinator, which is typical for African universities in H2020 where European institutions lead funding structures. Their 33 unique partners across 15 countries — from just 2 projects — confirms they have joined large, internationally diverse consortia rather than tight bilateral collaborations. This pattern suggests they are sought out specifically for what they bring geographically and contextually, not as a project management hub, making them a reliable specialist contributor rather than an administrative lead.
KNUST has connected with 33 distinct consortium partners across 15 countries through only 2 projects, indicating both projects involved large multinational teams — typical of RIA consortia with African field components. Their network is anchored in European research institutions but bridges into West Africa, a geographic node that few other H2020 participants can offer.
What sets them apart
As one of the few H2020 participants from Sub-Saharan Africa, KNUST occupies a rare position: a technically capable African university with demonstrated experience in both environmental data science and clinical vaccine research conducted under international quality standards. For any consortium requiring field validation, clinical trial sites, or data collection in West Africa, KNUST provides access that European partners cannot substitute. Their dual-sector presence also makes them a flexible entry point for interdisciplinary projects bridging climate, agriculture, and health in African development contexts.
Highlights from their portfolio
- Vacc-iNTSThe largest and longest of KNUST's H2020 commitments (2019–2026, EUR 194,226), this Phase 1 vaccine trial for a disease that kills hundreds of thousands of African children annually places KNUST at the intersection of global health and clinical research infrastructure.
- TWIGAKNUST's entry into H2020 through a project using satellite and ground-based data assimilation to build weather and water services for African farmers — directly connecting earth observation technology to smallholder agricultural resilience.